406 related articles for article (PubMed ID: 17496888)
1. Diarylquinolines target subunit c of mycobacterial ATP synthase.
Koul A; Dendouga N; Vergauwen K; Molenberghs B; Vranckx L; Willebrords R; Ristic Z; Lill H; Dorange I; Guillemont J; Bald D; Andries K
Nat Chem Biol; 2007 Jun; 3(6):323-4. PubMed ID: 17496888
[TBL] [Abstract][Full Text] [Related]
2. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure.
Segala E; Sougakoff W; Nevejans-Chauffour A; Jarlier V; Petrella S
Antimicrob Agents Chemother; 2012 May; 56(5):2326-34. PubMed ID: 22354303
[TBL] [Abstract][Full Text] [Related]
3. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase.
Haagsma AC; Podasca I; Koul A; Andries K; Guillemont J; Lill H; Bald D
PLoS One; 2011; 6(8):e23575. PubMed ID: 21858172
[TBL] [Abstract][Full Text] [Related]
4. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor.
Huitric E; Verhasselt P; Koul A; Andries K; Hoffner S; Andersson DI
Antimicrob Agents Chemother; 2010 Mar; 54(3):1022-8. PubMed ID: 20038615
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor.
Huitric E; Verhasselt P; Andries K; Hoffner SE
Antimicrob Agents Chemother; 2007 Nov; 51(11):4202-4. PubMed ID: 17709466
[TBL] [Abstract][Full Text] [Related]
6. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
Andries K; Verhasselt P; Guillemont J; Göhlmann HW; Neefs JM; Winkler H; Van Gestel J; Timmerman P; Zhu M; Lee E; Williams P; de Chaffoy D; Huitric E; Hoffner S; Cambau E; Truffot-Pernot C; Lounis N; Jarlier V
Science; 2005 Jan; 307(5707):223-7. PubMed ID: 15591164
[TBL] [Abstract][Full Text] [Related]
7. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis.
Koul A; Vranckx L; Dendouga N; Balemans W; Van den Wyngaert I; Vergauwen K; Göhlmann HWH; Willebrords R; Poncelet A; Guillemont J; Bald D; Andries K
J Biol Chem; 2008 Sep; 283(37):25273-25280. PubMed ID: 18625705
[TBL] [Abstract][Full Text] [Related]
8. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria.
Petrella S; Cambau E; Chauffour A; Andries K; Jarlier V; Sougakoff W
Antimicrob Agents Chemother; 2006 Aug; 50(8):2853-6. PubMed ID: 16870785
[TBL] [Abstract][Full Text] [Related]
9. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline.
Guo H; Courbon GM; Bueler SA; Mai J; Liu J; Rubinstein JL
Nature; 2021 Jan; 589(7840):143-147. PubMed ID: 33299175
[TBL] [Abstract][Full Text] [Related]
10. Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.
Guillemont J; Meyer C; Poncelet A; Bourdrez X; Andries K
Future Med Chem; 2011 Sep; 3(11):1345-60. PubMed ID: 21879841
[TBL] [Abstract][Full Text] [Related]
11. The structure of the catalytic domain of the ATP synthase from
Zhang AT; Montgomery MG; Leslie AGW; Cook GM; Walker JE
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4206-4211. PubMed ID: 30683723
[TBL] [Abstract][Full Text] [Related]
12. TBAJ-876 Retains Bedaquiline's Activity against Subunits c and ε of
Sarathy JP; Ragunathan P; Shin J; Cooper CB; Upton AM; Grüber G; Dick T
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358589
[TBL] [Abstract][Full Text] [Related]
13. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.
Rouan MC; Lounis N; Gevers T; Dillen L; Gilissen R; Raoof A; Andries K
Antimicrob Agents Chemother; 2012 Mar; 56(3):1444-51. PubMed ID: 22155815
[TBL] [Abstract][Full Text] [Related]
15. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
16. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue.
Haagsma AC; Abdillahi-Ibrahim R; Wagner MJ; Krab K; Vergauwen K; Guillemont J; Andries K; Lill H; Koul A; Bald D
Antimicrob Agents Chemother; 2009 Mar; 53(3):1290-2. PubMed ID: 19075053
[TBL] [Abstract][Full Text] [Related]
17. Insights into the Physiology and Metabolism of a Mycobacterial Cell in an Energy-Compromised State.
Patil V; Jain V
J Bacteriol; 2019 Oct; 201(19):. PubMed ID: 31285242
[No Abstract] [Full Text] [Related]
18. Shortening the treatment of tuberculosis.
Mitchison DA
Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148
[No Abstract] [Full Text] [Related]
19. Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines.
Courbon GM; Palme PR; Mann L; Richter A; Imming P; Rubinstein JL
EMBO J; 2023 Aug; 42(15):e113687. PubMed ID: 37377118
[TBL] [Abstract][Full Text] [Related]
20. TMC207: the first compound of a new class of potent anti-tuberculosis drugs.
Matteelli A; Carvalho AC; Dooley KE; Kritski A
Future Microbiol; 2010 Jun; 5(6):849-58. PubMed ID: 20521931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
